Objective: Kinins mediate pathophysiological processes related to hypertension, pain and inflammation through the activation of two G protein-coupled receptors, named B 1 and B 2 . Although these peptides have been related to glucose homeostasis, their effects on energy balance are still unknown.
ccording to the World Health Organization, one billion people worldwide are overweight and at least 300 million are clinically obese (www.who.int). Besides the negative social stigma carried by obese individuals, obesity can cause or exacerbate many health problems, such as type II diabetes, cardiovascular diseases and some cancers (1, 2) . Thus, obesity is associated to increased mortality (3) and accounts for up to 7.8 % of the total health care expenses in developed countries (4) .
In 1994, Zhang et al. (5) contributed significantly to our understanding of the endocrine mechanisms underlying the regulation of body weight. The group identified a null mutation in the ob gene that led mice to a phenotype of severe obesity. The functions of the ob gene product, a 16 kDa cytokine called leptin, were further characterized by several subsequent studies. Traditionally, it has been shown that leptin acts in the arcuate nucleus of the hypothalamus inhibiting food intake and promoting energy expenditure (6) . Lately, it has been shown that leptin has a broad spectrum of action in many areas of the central nervous system and peripheral organs. For instance, it was shown that leptin prevents lipotoxicity in liver, skeletal muscle and pancreas by direct inhibition of triglyceride formation and stimulation of free fatty acid oxidation (7) . Mice lacking leptin (ob/ob) show hyperphagia, insulin resistance, hypothermia, reduced sympathetic activation and infertility, parameters that can be restored after administration of exogenous leptin (6, 8) . Despite the powerful metabolic actions of leptin, the therapeutic use of this hormone was initially frustrated by observations that plasma leptin levels were in fact elevated in obese individuals (9) , which indicated that obesity in humans was accompanied by leptin resistance rather than hypoleptinemia. More recently, various mechanisms for leptin resistance in obesity have been proposed. The two main hypotheses are the saturation of the leptin transport through the blood-brain barrier (10, 11) and the failure of components of the leptin receptor (ObRb) signaling pathway (12) . It was shown, for example, that the overexpression of the suppressor of cytokine signaling-3 (SOCS3) caused leptin resistance in different animal models of obesity, since it resulted in a strong reduction of the Ob-Rb signal transduction (13) . Therefore, the identification of alternative factors that potentiate leptin signaling may lead to useful therapeutic approaches to treat obesity.
The kallikrein-kinin system represents a group of proteins involved in the control of blood pressure, gastrointestinal tract mobility, inflammation, and pain induction (14, 15) . In this system, precursor proteins called kininogens are cleaved by kallikreins to release kinins, which can further be cleaved by carboxypeptidases to give rise to des-Arg-kinins. The main active kinins are bradykinin and its metabolite des-Arg 9 -bradykinin. Bradykinin and des-Arg 9 -bradykinin use distinct G protein-coupled receptors to exert their effects. Whereas bradykinin interacts with the B 2 receptor subtype, des-Arg 9 -bradykinin has higher affinity for the B 1 receptor (14) . Kinin B 2 receptors are constitutively expressed in most tissues and exert most functions attributed to the kallikrein-kinin system, including vasodilation and salt excretion (14, 16) . Conversely, the kinin B 1 receptor is thought to be strongly induced by inflammatory stimuli and to mediate processes of injury and pain (14, 15, 17) . Accordingly, kinin B 1 receptor knockout mice (B 1 -/-) are hypoalgesic, less responsive to lipopolysaccharide induced hypotension (18) and present inhibition of neutrophil migration into inflamed tissue (19) .
Evidence that kinins induce insulin sensitivity in adipocytes (20) and control insulin release by pancreatic cells (21, 22) indicate that the kallikrein-kinin system also participates in metabolic processes. However, the physiological relevance of this A system to energy homeostasis, as well as the contributions of the kinin B 1 receptor to these processes, is still not well understood. Recently, our group showed that the B 1 receptor mRNA is upregulated in the white adipose tissue, liver and hypothalamus of ob/ob mice (23), suggesting for the first time a correlation between obesity and the kinin B 1 receptor. Furthermore, we observed that des-Arg 9 -bradykinin administration in mice is able to increase blood leptin levels (24) . In the present report, we examined the consequences of B 1 receptor ablation on the etiopathology of obesity using two animal models, the high fat diet (HFD)-induced obesity and the obese ob/ob mice. In addition, we evaluated the effect of pharmacological inhibition of B 1 receptors on weight gain and food intake of mice under HFD. The results of these studies strongly support a role for the kinin B 1 receptor in controlling body weight and fat accumulation through a mechanism that may involve the modulation of leptin signaling. (26) . Briefly, respiratory exchanges and spontaneous activity signals of freely moving mice were computed at ten second intervals using a computer-assisted data acquisition program (ADDENFI metabolic chamber prototype).
RESEARCH DESIGN AND METHODS

Animals
Mice were housed individually in the metabolic cages at 10:00 am without food and the post absorptive resting-energy expenditure (~ basal metabolism) was measured between 4:00 pm and 6:00 pm. At 6:00 pm, we gave a 1 g meal of either control or high fat diet to the mice and computed the increase in energy expenditure in response to feeding (metabolism and RQ). Leptin sensitivity. To determine leptin sensitivity, we administered recombinant mouse leptin (R&D Systems) 40 µg/day/mouse i.p. during 4 days (at 5:00 pm) and evaluated food intake and/or weight loss. Food intake during 5 days prior to leptin injection was considered as the basal consumption (100 %). An independent group of fasted animals were killed 45 minutes after the first leptin bolus for hypothalamus collection, protein extraction and western blotting quantification of pSTAT3 and STAT3. SSR240612 chronic administration. ALZET micro-osmotic pumps (Alza Corp., Palo Alto, California, USA), set to deliver for 28 days either 3 mg of SSR240612 (Sanofi-Aventis, Paris, France)/kg of animal/day or vehicle (2% DMSO), were subcutaneously implanted in anesthetized C56Bl/6 mice under sterile conditions. Seven days after the implant, mice were submitted to HFD for 3 weeks. Body weight and food intake were assessed weekly in the period of one month before and after the implant. At the end of the treatment, pumps were checked for their contents and animals with filled ones were not considered in the data analysis. Statistical analysis. All values were expressed as mean ± SEM. Statistical analyses were carried out using two-tailed Student's unpaired t test to compare two independent groups, or ANOVA followed by Bonferroni's test to compare more than two. Significance was rejected at p > 0.05.
RESULTS
B 1
-/-mice are lean. To assess possible contributions of the kinin B 1 receptor to the regulation of satiety and adiposity in mice, we analyzed body weight, energy intake and adipose mass in standard or HFD fed B 1 -/-and wild type (WT) animals. Despite no differences were found in the body weight ( Fig. 1A) and energy intake (Fig. 1B ) between WT and B 1 -/-mice under control diet, a drastic reduction of fat mass was observed in the knockout animals under this condition ( Fig. 1C and D) . Lean mass, however, was increased in these mice, accounting for their normal body weight when compared to WT (Fig. 1C) . On the other hand, under HFD, B 1 -/-mice exhibited impaired energy intake ( Fig. 1B) and were remarkably refractory to the effect of the diet on body weight gain (Fig. 1A ). In addition, total adiposity and fat accumulation by adipocytes were dramatically reduced in B 1 -/-mice under both diets ( Fig. 1E and F) , whereas the number of fat cells in the gonadal depots was only decreased in B 1 -/-mice under standard diet (Fig. 1G) .
Obesity is normally associated with insulin resistance and glucose intolerance. Thus, we investigated these parameters in WT and B 1 -/-mice under standard or HFD. In agreement, B 1 -/-mice presented improved glucose tolerance and reduced insulin levels in both diets in comparison to the WT (online appendix), confirming our previous data showing increased insulin sensitivity in these mice (21) .
Next, we measured serum leptin levels ( Fig. 2A ) and the expression of leptin mRNA (Fig. 2B) and protein (Fig. 2C) (Fig. 3A) revealed that inhibition of weight gain observed in B 1 -/-mice under HFD could not be totally explained by decreased energy intake (Fig. 1B) . Therefore, we quantified the components of total energy expenditure under normal and high fat feeding in B 1 -/-and WT mice. No differences in resting energy expenditure, increase in energy expenditure in response to feeding and respiratory quotient (RQ, VCO2/VO2) in the post-absorptive state (4 h before meal and 8-12 h after meal) were observed between B 1 -/-and WT mice ( Table  1) . Under standard diet, RQ levels after feeding were above 1.0 in both groups, suggesting that de novo lipogenesis in response to carbohydrate ingestion is occurring in these animals at a similar extent. In contrast, under HFD, B 1 -/-mice exhibited a meal-induced increase in RQ that lasted 4 hours less than in WT mice ( Fig. 3B and C) , indicating that postprandial inhibition of lipid oxidation is significantly lower in these animals. In addition, B 1 -/-mice under high fat regimen expended significantly more energy with activity (+46.6 %, P < 0.002, Table 1 ). Together, these data suggest that B 1 -/-mice can resist HFD-induced weight gain in part due to increased energy expenditure with spontaneous activity and decreased inhibition of lipid oxidation in response to a fat meal. Hypersensitivity to leptin in B 1 -/-mice. Together, hypoleptinemia, protection against HFD-induced hyperleptinemia, elevated energy expenditure and reduced food intake under HFD suggest increased leptin responsiveness in B 1 -/-mice. To test this hypothesis, we administered exogenous leptin to B 1 -/-and WT mice and quantified daily food intake and phosphorylation of STAT3, a downstream component of the Ob-Rb signaling pathway, in the hypothalamus of these animals. Indeed, a stronger inhibitory effect of exogenous leptin on food intake in B 1 -/-mice was observed when compared to WT mice (Fig.   4A) .
Furthermore, the levels of phosphorylated STAT3 after leptin injection were significantly higher in the hypothalamus of B 1 -/-in comparison to WT mice (Fig. 4B ). In addition, we measured the expression of Ob-Rb mRNA in B 1 -/-and WT mice hypothalamus and found up-regulation of this transcript in B 1 -/- (Fig. 4C) . Moreover, the expression of SOCS3, a potent inhibitor of the Ob-Rb signaling, was decreased in B 1 -/-mice hypothalamus (Fig.  4D) . These data suggest that Ob-Rb signaling is facilitated in B 1 -/-mice, which could contribute to the inhibition of food intake and enhanced energy expenditure in these animals under HFD. Another aspect of leptin sensitivity, the passage of leptin through the blood-brain barrier, was addressed in B -/-mice had a tendency to an increased leptin passage to the brain, no significant differences were observed in relation to the WT mice (data not shown).
We also assessed kinin B 1 receptor mRNA expression in the hypothalamus of WT mice after 9 weeks of high fat regimen. Interestingly, we found higher levels of this mRNA in HFD-fed mice, in comparison to animals under standard diet (Fig. 4E) . Taken together, these results indicate that the kinin B 1 receptor may participate in the mechanism of leptin resistance in obesity. Kinin B 1 receptor deficiency does not protect ob/ob mice from obesity. In order to estimate the importance of leptin hypersensitivity to the phenotype of resistance to obesity in B 1 -/-mice, we generated mice lacking both B 1 receptor and leptin (ob/ob-B 1 -/-). In comparison to ob/ob mice, ob/ob-B 1 -/-had no differences in body weight (Fig. 5A ) and exhibited no significant morphological alterations, except for mildly heavier heart and kidney (data not shown). We also did not observe differences between the ob/ob and the ob/ob-B 1 -/-mice on daily food ingestion (Fig. 5B) and on some parameters of adiposity in these animals, including epididymal fat content (Fig. 5C ) and adipocyte volume ( Fig. 5D and E) and number (Fig. 5F ). These data suggest that leanness associated with kinin B 1 receptor deficiency may be dependent on the leptin signaling. Leptin is more effective to promote weight loss in ob/ob-B 1 -/-mice. Next, we performed daily injections of exogenous leptin to ob/ob-B 1 -/-and ob/ob mice and measured food intake, body weight and feed efficiency. Interestingly, we found that the first dose of leptin was more efficient to inhibit food intake (Fig. 6A) and to promote weight loss (Fig. 6B) in ob/ob-B 1 -/-mice in comparison to ob/ob. In addition, ob/ob-B 1 -/-presented a significant reduction of feed efficiency on the first day of leptin administration ( Fig. 6C) , indicating that weight loss in this condition is not exclusively due to inhibition of food intake. To corroborate these data, we quantified leptin-stimulated STAT3 phosphorylation in the hypothalamus of ob/ob-B 1 -/-and ob/ob mice. As expected, ob/ob-B 1 -/-showed increased levels of phosphorylated STAT3 after leptin induction (Fig. 6D) . These results bring forth the hypothesis that the kinin B 1 receptor may play a role in energy homeostasis through the modulation of leptin responsiveness. The kinin B 1 receptor antagonist SSR240612 inhibits HFD-induced weight gain, energy intake and feed efficiency in mice. In order to validate our findings using knockout models and to confirm the pathophysiological function of the kinin B 1 receptor in obesity, we pharmacologically blocked this receptor in mice for 28 days by chronic administration of the non-peptide orally active B 1 receptor antagonist SSR240612 (3 mg/ kg animal/ day) and measured body weight gain and food intake weekly during this period. In the first week, mice were fed with a standard diet and showed no significant differences in body weight (Fig. 7A) and energy intake (Fig. 7B) between the groups receiving SSR240612 or the vehicle. However, after being submitted to a HFD, mice receiving SSR240612, in comparison to the control mice, showed a clear inhibition in body weight gain (Fig.  7A) and energy intake (Fig. 7B) . In addition, feed efficiency under HFD was significantly decreased in mice treated with SSR240612 (Fig. 7C) . Thus, these data show ample evidence to support the hypothesis that kinin B 1 receptor blockade protects mice from weight gain.
DISCUSSION
Although significant progress has been made in the identification of genes contributing to metabolic diseases, many pieces of the puzzle are still missing. Our data indicate that one member of the kallikrein-kinin system, the kinin B 1 receptor, may be an important part in this scenario, since it seems to play a significant role in the regulation of food intake and energy expenditure exerted by leptin. Prior to this study, however, few relevant physiological roles had been attributed exclusively to the activation of the kinin B 1 receptor. Moreover, in most physiological processes in which the expression of B 1 receptors was observed, the kinin B 1 receptor was considered a secondary player, serving as an alternative in case of B 2 receptor deficiency (14, 27) . However, recent results from our group showed that kinin B 1 receptor activation modulates leptin homeostasis (24) . In addition, here we present sufficient evidence to support the idea that kinin B 1 receptors are in fact participating in essential metabolic processes.
The kinin B 1 receptor, like many inflammatory molecules, including TNFα (28) and LPS (29) , may act through redundant pathways to display both its inflammatory and metabolic actions. Similarly, leptin has inflammatory actions and strongly controls energy homeostasis (6), mainly by regulating satiety and potentiating many components of the total energy expenditure, including the energy expended with physical activity (8) and with fat oxidation (7, 30) . According to our data, leptin may be a key mediator of the metabolic actions of the kinin B 1 receptor. Firstly, despite the gain of fat tissue after the high fat regimen, B 1 -/-mice are completely protected against HFD-induced hyperleptinemia, suggesting that leptin is not correlated with adiposity levels in these mice. Further, ob/ob-B 1 -/-and ob/ob mice are similarly obese, indicating that leptin may be necessary for the kinin B 1 receptor to affect food intake and energy expenditure. Finally, B 1 receptor deficiency increases leptin responsiveness and exacerbates the effects of exogenous leptin on weight loss in ob/ob mice.
Although the precise mechanism underlying the interaction between the kinin B 1 receptor and the leptin signaling pathway is still unclear, accumulating evidence showing the presence of this receptor and other components of the kallikrein-kinin system in the hypothalamus of rodents and humans (23, 31, 32) lead us to the hypothesis that the modulation of leptin sensitivity by the B 1 receptor may involve a central phenomenon. In agreement, we observed more pronounced effects of exogenous leptin administration on food intake inhibition in B 1 -/-mice. These experiments, based on previously described protocols (8, 43, 44) , reflect observations obtained from daily injections of high doses of leptin, and may therefore represent supraphysiological effects. Nevertheless, increased central leptin sensitivity in B 1 -/-mice is corroborated by increased leptininduced STAT3 phosphorylation, as well as up-regulation of Ob-Rb mRNA and reduced levels of SOCS3 under basal conditions in the hypothalamus of these animals.
SOCS3 is a member of a family of cytokine-inducible suppressors of cytokine signaling that particularly inhibits leptin signal transduction (13) . In mouse embryonic fibroblasts, TNFα-dependent activation of the nuclear factor κB (NF-κB) is able to induce SOCS3 expression and, consequently, elicit negative effects on STAT signaling (33) . As an inflammatory mediator, the kinin B 1 receptor can also activate NF-κB (34) . Therefore, a possible mechanism to explain the down-regulation of SOCS3 in B 1 -/-mice would be a reduction of B 1 receptor-induced NF-κB activity in Ob-Rb neurons. Moreover, B 1 receptor deficiency could lead to an understimulation of the hypothalamic cytokine signaling due to a decrease in cytokine production. Studies have shown that kinins can induce TNFα and IL-1 release from macrophages (35) and IL-6 expression by astrocytes (36) .
Obesity has also been linked to increased inflammation and macrophage infiltration in the adipose tissue (37) . It is postulated that cytokines produced by the adipose tissue, which include leptin, TNFα and some interleukins, are pivotal factors in the control of metabolism. In previous studies, B 1 receptor deficiency has been associated with hypoalgesia and reduced inflammatory response (18, 19) . It was demonstrated that the hypotensive effect of LPS was blunted in B 1 -/-mice, as well as the infiltration of polymorphonuclear leukocytes into tissues. The contributions of the kinin B 1 receptor to the inflammatory status of the adipose tissue is, however, not clear. Thus, future experiments may be proposed to understand how the absence of B 1 receptors in the adipose tissue could modulate inflammatory mediators to participate in the phenotypes observed in B 1 -/-mice.
On the other hand, the regulation of the energy balance by kinin B 1 receptor may not be related exclusively to activation by kinins. Recently, Lai et al. (38) presented strong evidence that kinins are not the only agonists that bind to kinin receptors. They showed that the endogenous opioid peptide dynorphin A promotes neuropathic pain through the activation of both kinin B 1 and B 2 receptors. In the early 80s, three years after dynorphins were identified as opioid regulators of pain and stress responses, these peptides were described as potent inducers of food intake (39, 40) . However, in two decades, modest advances have been made to provide a solid understanding of the mechanisms mediating the regulation of energy balance by dynorphin. Nevertheless, evidence showing that dynorphin neurons in the arcuate nucleus are leptin responsive (41) and that the effect of kappa opioid agonists on food intake can not be reproduced in ob/ob mice (42) indicate that leptin may be required for this event to happen. Thus, we speculate that dynorphin may act through the kinin B 1 receptor to control food intake via modulation of the leptin signaling.
In general, protection against obesity is a common feature of mice with leptin hypersensitivity. SOCS3 gene disruption in the brain, for instance, is able to increase leptin sensitivity and promote resistance to HFD-induced weight gain and hyperleptinemia (43) . Moreover, the neuron-specific tyrosine phosphatase PTP1B knockout mice are overresponsive to the effects of exogenous leptin and show reduced adiposity and elevated energy expenditure with activity (44) . Thus, targeting SOCS3 and PTP1B are currently considered attractive strategies to fight obesity and diabetes.
Similarly, CB 1 cannabinoid receptor knockout mice (45, 46) are more sensitive to intracerebroventricular injections of leptin, have decreased body weight and are slightly hypophagic. In addition, they are resistant to HFD-induced weight gain due to an increase in energy expenditure. Based on this animal model, researchers evidenced a strong antiobesity effect of the CB 1 receptor antagonist SR141716A (46) , and currently, under the name of rimonabant, this drug has been considered the most efficient clinical therapy to treat human obesity (47) . Therefore, based on the presented data, we suggest here the orally active kinin B 1 receptor antagonist SSR240612 as a potential tool to prevent obesity. Although several experiments still must be addressed in order to verify the clinical relevance of this drug, we believe that our results and the grown body of evidence showing limited expression of B 1 receptors under physiological conditions (14) may render the kinin B 1 receptor an interesting potential target to treat obesity with low risks of severe side effects.
In summary, we have presented in this study consistent data indicating that functional deficiency of the kinin B 1 receptor can protect mice from obesity through a mechanism that may involve leptin signaling.
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